Differential intracellular processing of the anthracycline drug ME2303 in doxorubicin‐sensitive (A2780) and ‐resistant (A2780AD) human ovarian cancer cells as studied with confocal laser scanning microscopy and image analysis

Laser scanning confocal microscopy has been used to follow the uptake and efflux of the 2‐fluoroglycoside of doxorubicin, ME2303, in live cultures of the human ovarian cancer cell line A2780 and its doxorubicin‐resistant variant A2780AD. Our methods combine confocal laser scanning microscopy and image analysis to examine the dynamics of anthracycline drugs in cancer cells. Cytotoxicity determined by MTT dye reduction showed that A2780AD cells were more than 400 times less sensitive to doxorubicin compared to A2780 cells but almost 9 times more sensitive to ME2303 compared to doxorubicin. The naturally fluorescent drug was tracked within live cells at 37°C to provide time‐course information in relation to nuclear and Golgi‐associated cellular domains, as indicated by BODIPY FL ceramide‐associated fluorescence. In both cell types, ME2303 was characterised by strong nuclear membrane and peri‐nucleolar fluorescence and as a localised punctate pattern within the nucleus. A2780AD cells accumulated ME2303 in their nuclei at a much reduced rate compared to the doxorubicin‐sensitive cells, and ME2303 efflux from resistant cell nuclei was approximately twice as fast as from A2780 cells. The relative uptake of ME2303 into Golgi‐associated domains and the nucleus were monitored simultaneously during the initial 35 min of exposure to 10 μM ME2303 and during the first 45 min of a “chase” culture following exposure to 20 μM ME2303. ME2303 was detectable within the Golgi‐associated domains of A2780 cells several minutes later and in less relative concentration than in A2780AD cells 15 min into a chase culture. Our results suggest the direct involvement of differences in drug processing via the Golgi apparatus in the expression of P‐glycoprotein‐related drug resistance.

[1]  J. Baak,et al.  Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells. , 1993, British Journal of Cancer.

[2]  Hamid Morjani,et al.  Confocal fluorescence microscopy of living cells , 1993, Other Conferences.

[3]  P. Workman,et al.  Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines. , 1993, British Journal of Cancer.

[4]  P. Workman,et al.  Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance. , 1992, Anti-cancer drug design.

[5]  K. Kiura,et al.  Comparison of antitumor activity of new anthracycline analogues, ME2303, KRN8602, and SM5887 using human lung cancer cell lines. , 1992, Acta medica Okayama.

[6]  D. Marquardt,et al.  Drug transport mechanisms in HL60 cells isolated for resistance to adriamycin: evidence for nuclear drug accumulation and redistribution in resistant cells. , 1992, Cancer research.

[7]  J. Baak,et al.  Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. , 1991, British Journal of Cancer.

[8]  A. Hoshi,et al.  Antitumor Activity and Metabolism of a New Anthracycline‐containing Fluorine (ME2303) in Lewis Lung Carcinoma‐bearing Mice , 1991, Japanese journal of cancer research : Gann.

[9]  J. Gervasoni,et al.  Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. , 1991, Cancer research.

[10]  S. Mirski,et al.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. , 1991, Cancer research.

[11]  M. Dietel,et al.  Morphologic alterations in drug sensitive vs. drug resistant cells due to cytostatic application. , 1990, Cancer treatment reviews.

[12]  H. Tapiero,et al.  Can cytotoxic activity of anthracyclines be related to DNA damage? , 1990, Anti-cancer drug design.

[13]  T. Tsuruo,et al.  A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. , 1989, Cancer research.

[14]  S. Kaye,et al.  Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. , 1989, Cancer research.

[15]  K. Bhalla,et al.  Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. , 1989, Cancer research.

[16]  F. Arcamone Clinically useful doxorubicin analogues. , 1987, Cancer treatment reviews.

[17]  I. Pastan,et al.  Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. , 1986, Cancer research.

[18]  E. Modest,et al.  Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. , 1976, Cancer research.

[19]  N. Bachur,et al.  Cytofluorescence localization of adriamycin and daunorubicin. , 1974, Cancer Research.

[20]  Marc Buyse,et al.  Cyclophosphamide Plus Cisplatin Versus Cyclophosphomide, Doxorubicin, and Cisplatin Chemotherapy of Ovarian-carcinoma - a Metaanalysis , 1991 .